Trinayan Kashyap
Karyopharm Therapeutics (United States)(US)
Publications by Year
Research Areas
Nuclear Structure and Function, Cancer-related Molecular Pathways, RNA Research and Splicing, Cancer, Lipids, and Metabolism, Immunotherapy and Immune Responses
Most-Cited Works
- → CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications(2013)302 cited
- → A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia(2017)149 cited
- → Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death(2016)129 cited
- → XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus(2016)94 cited
- → XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma(2016)89 cited
- → Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis(2017)71 cited
- → Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents(2018)68 cited
- → Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies(2020)67 cited
- → Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer(2015)61 cited
- → Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo(2021)55 cited